KaufmanJM, VermeulenA. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev, 2005; 26:833–876.
2.
WangC, NieschlagE, SwerdloffRet al.Investigation, treatment, monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol, 2008; 159:507–514.
ZitzmannM. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol, 2007; 4:161–166.
5.
ZitzmannM, BruneM, KornmannBet al.The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab, 2001; 86:4867–4873.
6.
ZitzmannM, NieschlagE. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab, 2007; 92:3844–3853.
7.
VermeulenA, VerdonckL, KaufmanJM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab, 1999; 84:3666–3672.
8.
WangC, CatlinDH, DemersLM, StarcevicB, SwerdloffRS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab, 2004; 89:534–543.
9.
BhasinS, WoodhouseL, CasaburiRet al.Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab, 2001; 281:1172–1181.
10.
MorgentalerA, TraishAM. Shifting the paradigm of testosterone, prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol, 2009; 55:310–320.
11.
StanworthR, KapoorD, ChannerK, JonesT. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol, 2008; 159:739–746.
12.
ZitzmannM, FaberS, NieschlagE. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab, 2006; 91:4335–4343.
13.
LimerKL, PyeSR, ThomsonWet al.the EMAS study group. Genetic variation in sex hormone genes influences heel ultrasound parameters in middle aged, elderly men: Results from the European Male Ageing Study (EMAS)J Bone Miner Res, 2009; 24:314–323.
14.
HuhtaniemiIT, PyeSR, LimerKLet al.the EMAS study group. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab, 2009; 94:277–284.
15.
ShabsighR, ArverS, ChannerKSet al.The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract, 2008; 62:791–798.
16.
SchneiderG, NienhausK, GromollJ, HeuftG, NieschlagE, ZitzmannM. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology, 2010; 35:578–587.
17.
SchneiderG, NienhausK, GromollJ, HeuftG, NieschlagE, ZitzmannM. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry, 2011; 19:274–283.
18.
SchneiderG, NienhausK, GromollJ, HeuftG, NieschlagE, ZitzmannM. Sex hormone levels, genetic androgen receptor polymorphism, and anxiety in ≥50-year-old males. J Sex Med, 2011; 8:3452–3464.
19.
FrancomanoD, GrecoEA, LenziA, AversaA. CAG repeat testing of androgen receptor polymorphism: Is this necessary for the best clinical management of hypogonadism?J Sex Med, 2013; 10:2373–2381.
